Quarterly ResultAug 6, 2026, 07:33 AM
InflaRx Q2 2026 Net Loss €16.2M; Cash Runway Through 2029
AI Summary
InflaRx N.V. reported its Q2 2026 financial results, showing a net loss of €16.2 million for the six months ended June 30, 2026. The company announced a strong financial position with €158.4 million in cash, cash equivalents, and marketable securities, projecting a cash runway through 2029. InflaRx also provided a business update, highlighting the advancement of izicopan in ANCA-associated vasculitis (AAV) and select renal diseases, with clinical preparations ongoing and a pharmacokinetic bridging study in China expected to start late this year. A Virtual Capital Markets Day is planned for October 8, 2026.
Key Highlights
- Cash, cash equivalents, and marketable securities totaled €158.4 million as of June 30, 2026.
- Cash runway is expected to fund operations and clinical development through 2029.
- Net loss for the six months ended June 30, 2026, was €16.2 million.
- Loss per ordinary share for the six months ended June 30, 2026, was €0.17.
- Net proceeds from the May 2026 public offering were €119.3 million ($140.4 million).
- Research and development expenses decreased by €5.3 million to €8.9 million for the six months ended June 30, 2026.
- General and administrative expenses decreased by €2.6 million to €5.7 million for the six months ended June 30, 2026.
Price Impact
More from IFRX